» Articles » PMID: 19891557

Host Genetic Determinants of Spontaneous Hepatitis C Clearance

Overview
Specialties Genetics
Pharmacology
Date 2009 Nov 7
PMID 19891557
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Acute infection with the hepatitis C virus (HCV) induces a wide range of innate and adaptive immune responses. A total of 20-50% of acutely HCV-infected individuals permanently control the virus, referred to as 'spontaneous hepatitis C clearance', while the infection progresses to chronic hepatitis C in the majority of cases. Numerous studies have examined host genetic determinants of hepatitis C infection outcome and revealed the influence of genetic polymorphisms of human leukocyte antigens, killer immunoglobulin-like receptors, chemokines, interleukins and interferon-stimulated genes on spontaneous hepatitis C clearance. However, most genetic associations were not confirmed in independent cohorts, revealed opposing results in diverse populations or were limited by varying definitions of hepatitis C outcomes or small sample size. Coordinated efforts are needed in the search for key genetic determinants of spontaneous hepatitis C clearance that include well-conducted candidate genetic and genome-wide association studies, direct sequencing and follow-up functional studies.

Citing Articles

Immunomodulatory Role of Interferons in Viral and Bacterial Infections.

Mertowska P, Smolak K, Mertowski S, Grywalska E Int J Mol Sci. 2023; 24(12).

PMID: 37373262 PMC: 10298684. DOI: 10.3390/ijms241210115.


Sequence diversity of hepatitis D virus in Mongolia.

Magvan B, Kloeble A, Ptok J, Hoffmann D, Habermann D, Gantumur A Front Med (Lausanne). 2023; 10:1108543.

PMID: 37035318 PMC: 10077969. DOI: 10.3389/fmed.2023.1108543.


The HCV Envelope Glycoprotein Down-Modulates NF-κB Signalling and Associates With Stimulation of the Host Endoplasmic Reticulum Stress Pathway.

McKay L, Thomas J, Albalawi W, Fattaccioli A, Dieu M, Ruggiero A Front Immunol. 2022; 13:831695.

PMID: 35371105 PMC: 8964954. DOI: 10.3389/fimmu.2022.831695.


Association between polymorphisms and interferon/ribavirin treatment response in hepatitis C virus type 1 infection in Chinese population: a prospective study.

Yao Y, Liu M, Zang F, Yue M, Xia X, Feng Y BMJ Open. 2018; 8(4):e019406.

PMID: 29654010 PMC: 5898346. DOI: 10.1136/bmjopen-2017-019406.


Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C.

Zaily D, Marlen C, Santiago D, Gillian M, Carmen V, Zurina C Curr Ther Res Clin Exp. 2017; 85:20-28.

PMID: 29158855 PMC: 5681293. DOI: 10.1016/j.curtheres.2017.04.006.